Effects of Adalimumab Entering National Reimbursement on Medical Costs for Patients With Psoriasis:A 4-Year Single-Center Retrospective Study in China

扫码查看

原文链接

NETL
NSTL
万方数据

外文摘要：Objective:Adalimumab(ADA)is expensive and rarely used among patients.However,its cost for moderate to severe chronic plaque psoriasis can now be reimbursed since its addition to the National Reimbursement Drug List(NRDL)in January 2020.Therefore,we conducted this study to estimate the medical cost of ADA and its influencing factors in patients with psoriasis using ADA and thus gain a better understanding of the effect of the NRDL adjustment in China.Methods:This retrospective study evaluated the medical cost of ADA before and after the addition of ADA to the NRDL(2018-2022)among 320 patients in a large professional dermatology specialty hospital.Descriptive analysis,Welch's analysis of variance,and multiple regression analysis were used to evaluate the medical cost and influencing factors.Results:Before ADA was added to the NRDL,patients'mean total cost and ADA cost were ¥24,243.56±16,346.53 and ¥20,391.11±14,440.69,respectively.After ADA became covered by the NRDL,the above 2 expenses decreased to ¥10,461.19±7,554.66 and ¥8,775.27±7,092.16,respectively.This significant decrease in the cost of ADA resulted in a significant 110.5-times increase in ADA use.Statistically significant differences were found in the total cost,patient type(outpatient/inpatient),insurance status(yes/no),reimbursement status(before/after),and age.Medical insurance reimbursement(P＜0.001,β=-0.468,before reimbursement=1,after reimbursement=2)was the most significant influencing factor,followed by patient type(P=0.018,β=-0.215,outpatient=1,inpatient=2)and age(P=0.0046,β=-0.174).Conclusion:Medical insurance reimbursement is the most important factor affecting patients'total cost of ADA by reducing the economic burden,enhancing the availability of ADA,and stimulating the need for treatment.

外文关键词：

adalimumabbiological agentpsoriasismedical costmedical insurance

作者：

Yu Li、Bo-Kun Zhu、Qing-Sheng Min、Mei Ju、Min Li

展开 >

作者单位：

Department of Medical Affairs,Hospital for Skin Diseases(Institute of Dermatology),Chinese Academy of Medical Sciences and Peking Union Medical College,Nanjing,Jiangsu 210042,China

Hospital Network Information Center,Hospital for Skin Diseases(Institute of Dermatology),Chinese Academy of Medical Sciences and Peking Union Medical College,Nanjing,Jiangsu 210042,China

Department of Physiotherapy,Hospital for Skin Diseases(Institute of Dermatology),Chinese Academy of Medical Sciences and Peking Union Medical College,Nanjing,Jiangsu 210042,China

Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs,Hospital for Skin Diseases(Institute of Dermatology),Chinese Academy of Medical Sciences and Peking Union Medical College,Nanjing,Jiangsu 210042,China

展开 >

基金：

Chinese Academy of Medical Sciences Medicine and Health Technology Innovation Project

项目编号：

2017-I2M-1-017

出版年：

2024

DOI：

10.1097/JD9.0000000000000310

国际皮肤性病学杂志

中华医学会,中国医学科学院皮肤病研究所

国际皮肤性病学杂志

CSTPCD

影响因子：0.276

ISSN：1673-4173

年,卷(期)：2024.7(2)